EQS-News: Gerresheimer Adjusts Guidance for Financial Year 2025

Gerresheimer Adjusts Guidance for Financial Year 2025

• Preliminary results for Q2 2025: Low-single-digit organic revenue growth, adjusted EBITDA margin around 19%
• Continued subdued demand in the cosmetics market
• Temporary decline in demand for containment solutions for oral liquid medications
• New dividend proposal of 4% of share capital
• Long-term growth prospects remain intact

Duesseldorf, June 2, 2025. Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, is adjusting its guidance for 2025. This is due to continuing subdued demand in the cosmetics market and a decline in demand for plastic containment solutions for oral liquid medications, which the company considers to be temporary. Organic revenue growth in the second quarter of 2025 is expected to be in the low single-digit percentage range compared to the same period of the previous year, while the adjusted EBITDA margin will be around 19%. This means that overall growth and the EBITDA margin in the first half of 2025 will be lower than anticipated. Even taking into account the expected significantly stronger second half of 2025, the original guidance for the 2025 financial year will therefore not be achievable. In the 2025 financial year, the company now expects organic revenue growth of 1 to 2% compared to the previous year (previously: 3 to 5%) and an Adjusted EBITDA margin of around 20% (previously 22%). Adjusted EPS will decline in the low double-digit percentage range compared to the previous year (previously: growth in a high single-digit percentage range). The long-term growth prospects of the company remain intact. In view of the guidance adjustment for 2025, the Executive Board has decided to submit a new dividend proposal to the Annual General Meeting on June 5, 2025, to maintain the company's financial flexibility. According to this proposal, the dividend to be paid for the 2024 financial year will be reduced to the minimum of 4% of the share capital, this corresponds to EUR 0.04 per share instead of the previous EUR 1.25 per share. The Supervisory Board will promptly discuss such an adjustment to the dividend proposal. 

“We will return to organic revenue growth in the second quarter of 2025, but the growth momentum in some areas of our business is lower than expected given the current developments in the overall economy and in our industry. We therefore need to adjust our growth expectations for the full year,“ explains Dietmar Siemssen. ”Our long-term growth prospects remain positive, particularly for containment solutions and drug delivery systems for biologics, including the GLP-1 business.”

Organic growth in Q2 2025 with subdued dynamics

Based on preliminary figures for the second quarter, Gerresheimer expects organic sales growth in the low single-digit percentage range and an adjusted EBITDA margin of around 19%. Realized revenues in the syringe business, which had been deferred from the first to the second quarter of 2025, contributed to organic growth. However, the results for the second quarter will be impacted by the temporary weakness in demand in the cosmetics market and for containment solutions for oral liquids. This means that overall growth in the first half of 2025 will be lower than anticipated.

New dividend proposal of 4% of share capital

In light of current developments, the Management Board has decided to submit a new dividend proposal for the 2024 financial year to the Annual General Meeting on June 5, 2025. This is intended to maintain the company's financial flexibility. Accordingly, only the minimum dividend of 4% of the share capital is supposed to be distributed for the 2024 financial year, corresponding to a dividend of 4 cents per share. The Supervisory Board will promptly discuss such an adjustment to the dividend proposal. 

New guidance for Financial Year 2025 – organic growth to continue

Gerresheimer expects growth to pick up significantly again in the second half of 2025. However, this is unlikely to fully offset the lower growth momentum in the first half of 2025. The company has therefore adjusted its growth guidance for financial year 2025 and now expects organic revenue growth of 1 to 2% compared with the previous year and an adjusted EBITDA margin of around 20%. Growth drivers in the second half of the year will be the resumption of full production in Morganton and Lohr, systems and solutions for biologics, the ramp-up of new production lines thanks to the successful implementation of growth projects, and the expanded portfolio of high-value solutions. Gerresheimer will provide a full update on the Q2 and H1 results for 2025, as well as on the mid-term guidance, on July 10, 2025, as scheduled.

Long-term outlook remains positive

Gerresheimer's long-term outlook remains positive. The Group has a broad portfolio of systems and solutions for the pharma and biotech industries, with a growing share of specific solutions for biologics and other high-value solutions. The acquisition of Bormioli Pharma has further expanded the portfolio and opened up new opportunities for system integration.

Adjusted Guidance for FY 2025

• Revenue growth: 1-2% (organic)
• Adjusted EBITDA margin: ~ 20% (organic)
• Adjusted EPS growth: decline in the low double-digit percentage range
  (currency-adjusted)

About Gerresheimer 
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenues of around EUR 2.4bn in 2024 and currently employs around 13,400 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).    
www.gerresheimer.com 

Contact Gerresheimer AG